The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Lana Bridi und 8 weiteren Autor:innen. Beteiligte Einrichtung: MASLD Research Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Elasticity Imaging Techniques. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, Gilead Sciences.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Genetic factors contribute to the risk and severity of metabolic dysfunction‐associated steatotic liver disease (MASLD). However, the utility of genetic testing in risk stratification remains poorly characterised.
Aims
To examine the influence of genetic risk on advanced fibrosis and cirrhosis in patients with type 2 diabetes mellitus (T2DM) and the utility of a polygenic risk score (PRS) in screening guidelines.
Methods
We prospectively enrolled adults aged ≥50 years with T2DM recruited from clinics. PRS was the sum of risk alleles in PNPLA3 , TM6SF2 and SERPINA1 minus the protective variant in HSD17B13 . We performed magnetic resonance elastography and vibration‐controlled transient elastography to assess for advanced fibrosis and cirrhosis.
Results
Of 382 included patients, the mean age and BMI were 64.8 (±8.4) years and 31.7 (±6.2) kg/m 2 respectively. The prevalence of advanced fibrosis and cirrhosis were 12.3% and 5.2% respectively; higher PRS was associated with increased risk of cirrhosis (2.7% vs. 7.5%, p = 0.037). High PRS was associated with increased risk of advanced fibrosis among those with fibrosis‐4 index (FIB‐4) index
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MASLD Research Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Verve Therapeutics, Boston, Massachusetts, USA.
- Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
ORCID-Profile: Rohit Loomba, Veeral Ajmera
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- Gilead Sciences
- John C Martin Foundation
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
Zitieren
APA
Bridi, L., Agrawal, S., Tesfai, K., Madamba, E., Bettencourt, R., Richards, L. M., Khera, A. V., Loomba, R., & Ajmera, V. (2024). The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18099
Vancouver
Bridi L, Agrawal S, Tesfai K, Madamba E, Bettencourt R, Richards LM, et al. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18099
BibTeX
@article{Bridi2024,
author = {Bridi, Lana and Agrawal, Saaket and Tesfai, Kaleb and Madamba, Egbert and Bettencourt, Ricki and Richards, Lisa M and Khera, Amit V and Loomba, Rohit and Ajmera, Veeral},
title = {The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18099}
}
EUVIMED